Molecular Partners H1 FY26 net loss narrows to CHF 26.7 million; operating loss improves to CHF 27 million
MOLN•MP0712 advances in Phase 1/2a
- MP0712 advanced to cohort 2 in Phase 1/2a at 105 MBq per dose with no dose-limiting events in cohort 1.
- Initial data are expected in 2026.
H1 FY26 financial results improve
- Molecular Partners posted a net loss of CHF 26.7 million, narrowing from CHF 37.2 million in H1 2025.
- Operating loss narrowed to CHF 27.0 million; total operating expenses fell 19.4% to CHF 27.0 million.
- R&D expense dropped 15.93% to CHF 19.0 million; net cash used in operating activities decreased 17.22% to CHF 25.0 million.
- Cash and cash equivalents totaled CHF 67.9 million, funding operations into late 2027; full-year operating expenses are forecast at CHF 45-55 million.
